A Clinical Study of VA-CAG as Induction Therapy in Newly Diagnosed AML Patients
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
This study aims to assess the therapeutic efficacy and safety of venetoclax in combination
with azacitidine and CAG(VA-CAG) as induction regimen in newly diagnosed young patients with
acute myeloid leukemia(AML).